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AnticancerAbstract On account of the reported anticancer of pyrimidine and condensed pyrimidine, a new
pyrimido [3,2-b]-1,2,4,5-tetrazine 3a,b, 5c,d, 6, 9, pyrimido [3,2-b]-1,2,4-triazine 10, 11, pyrimido
[3,2-b]-1,2,4-triazole 12 and pyrimidine derivatives 1,2a,b, 4c,d, 8, 13, 14, 15 and 16 were synthesized
through different chemical reactions. Structures of all synthesized compounds were supported by
spectral and elemental analyses. The obtained compounds were evaluated for their in vitro antitu-
mor activity against human liver cancer cell line (HEPG2).
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Pyrimidine and condensed pyrimidine are important classes of
heterocyclic compounds that exhibit a broad spectrum of bio-
logical activities such as anticancer (Araguchi et al., 2004;
Breault et al., 2000; Kim et al., 2003; Deng et al., 2008; Abou
El Ella et al., 2008; Nguyen, 2008), antiviral (Depecker et al.,
2004; Renau et al., 1996), antibacterial (Kuyper et al., 1996;
Gregory et al., 2007), antioxidant (Andrus et al., 1997; Bundy
et al., 1995), anxiolytic (Meada et al., 1998) and antidepressant
activities (Hogenkamp et al., 2001).
Among its fused bicyclics, the pyrimido [1,2-b]-1,2,4,5-tet-
razin-6-ones have inhibitory activity against the human cyto-
megalovirus (HCMV) protease (Martin et al., 2003).Pyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-dione derivatives
confer signiﬁcant cytoprotective effects from rotenone toxicity
in a cellular rotenone stress assay and Parkinson’s disease
(Zhou et al., 2009). Also, pyrimido[5,4-3]-1,2,4-triazine-5,7-
diamine based––hypoglycemic agents with protein tyrosine
phosphatases inhibitory activity (Kevin et al., 2003).
Fused azoloazine systems have attracted attention due pri-
marily to the fact that they are widespread among natural bio-
logically active compounds (Sidorenko et al., 2010).
Among the nitrogen containing heterocycles triazolopyri-
midines represent a pharmaceutically important class of com-
pounds because of their diverse range of biological activities
such as antitumor (Navarro et al., 1998), cytotoxicity (Magan
et al., 2004), therapeutic potentiality (Magan et al., 2005). Po-
tent and selective ATP site directed inhibition of the EGF re-
ceptor protein tyrosine kinase (Traxler et al., 1996) and
cardiovascular (Rusinov et al., 1986) activities. In addition,
they have been found in DNA-interactive drugs (Lauria et
al., 2002). Pyrimidine derivatives are attractive due to their
pharmacological activity (Foroughifar et al., 2002; Tsuji and
Ishikawa, 1994) and possess antiviral (Varma, 1999) antitumor
(Kappe et al., 1997), antibacterial (Xie et al., 1999; Kappe,
306 S.A. Al-Issa1993), antihypertensive (Atwal et al., 1991), and antitubercu-
lous properties (Patel et al., 2006) and effective against wild
type and various mutant strains of HIV-1 (Ludovici and
Janseen, 2004). In light of the aforementioned facts.y I envi-
sioned our approach toward the synthesis of novel pyrimi-
do[2,3-b]-1,2,4,5-tetrazine, pyrimido[2,3-b]-1,2,4-triazine,
pyrimido[2,3-b]-1,2,4-triazole and pyrimidine derivatives to
evaluate their potential anticancer activities.NCOR'
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The starting material 1-amino-4-methyl-6-phenyl pyrimidin-2-
thione was prepared in good yields by the reaction of benzoy-
lacetone and thiosemicarbazide in reﬂuxing ethanol containing
catalytic amounts of piperidine afforded a pale yellow product
1 (Scheme 1). The structure of compound 1 was established on
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a molecular ion corresponding to the formula C11H11N3S (M
+
217). Its IR spectrum revealed absorption bands due to NH2,
C‚N and C‚S groups near 3361, 3308, 1644 and 1216 cm1,
respectively. The 1H NMR spectrum revealed (CH3) protons
as a singlet signal around d 2.35 ppm, singlet at d 5.70 ppm as-
signed to the NH2 protons, singlet at d 8.65 ppm assigned to
the H-5 pyrimidine ring and multiplet at d 7.30–8.20 ppm as-
signed to the aromatic protons. Thenoyl isothiocyanate (Cop-
po and Fawzi, 1997) or phenyl isothiocyanate reacted with
compound 1 to give N-thenoyl or (N-phenyl)-N0-1-[(4-
methyl-6-phenyl-2-thioxo pyrimidinyl] thiourea 2a,b. The IR
spectrum of compound 2a showed the absence of an absorp-
tion band corresponding to the amino group and the appear-
ance of new bands corresponding to (2NH) at 3242,
3135 cm1 and 1H NMR showed signals at 12.79 and
10.00 ppm for (2NH).
Treatment of 2a or b with hydrazine hydrate afforded 9-
methyl-7-phenyl-4-(2-thenoyl amino (or) phenyl amino)-(3H)
pyrimido[3,2-b]-1,2,4,5-tetrazine 3a,b. This reaction proceeds
through the initial formation of the intermediate 20, followed
by interamolecular cyclization and loss of hydrogen sulﬁde
(lead acetate paper). The structure of compounds 3a,b was con-
ﬁrmed by elemental analysis and their spectral data. The IRN
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Schemespectra of compound 3a showed strong absorption bands in
the region 3305, 3259 cm1 to NH tetrazine ring and NH of
secondary amine.
The absorption bands of the aroyl carbonyl for compound
3a were found at, 1665 cm
1 region. In the 1H NMR spectrum,
the signal of NH proton of tetrazine ring recorded at 9.85 ppm
(Hany and Hazem, 2008). The 13C NMR spectrum showed the
expected resonance signal of C-5 of tetrazine ring around
111.00 ppm. This assignment is in good agreement with litera-
ture data for carbon ﬂanked by two nitrogens and azomethine
carbon in six-membered heterocycles (El-Abadelah et al.,
1988). The mass spectrum of 3a showed a molecular ion peak
m/z at 350 (M+, 2.72%).
Treatment of compound 1 with acetyl chloride or thenoyl
chloride in pyridine resulted in the formation of the 1-(carbox-
amide (or) 2-thenoylamino)-4-methyl-6-phenyl-pyrimidine-2-
thion 4c–d. The IR spectrum of compound 4c showed a strong
band in the region of 1695 cm1 characteristic of C‚O of sec-
ondary amide. The two bands in the region of 3190, 3320 cm1
are the stretching modes of HNCO and N‚C–OH groups.
The 1H NMR of 4c showed a singlet at d 9.98, 10.76 ppm
(1H, HNC‚O or N‚C–OH) and a singlet at d 11.33 ppm
(1H, HNCOCH3(. Compounds 5c or d were prepared, under fu-
sion condition of compounds 4c or d with hydrazine hydrate toS
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Figure 1 Sample No. 1. The inhibitory effect of compound 1
concentration on HEPG2 cells activity.
Figure 2 Sample No. 2a. The inhibitory effect of compound 2a
concentration on HEPG2 cells activity.
Figure 3 Sample No. 2b. The inhibitory effect of compound 2b
concentration on HEPG2 cells activity.
308 S.A. Al-Issafurnish the 4,9-dimethyl-7-phenyl-(3H) pyrimido[3,2-b]-
1,2,4,5-tetrazine 5c and 9-methyl-7-phenyl-4-(2-thienyl)(3H)
pyrimido[3,2-b]-1,2,4,5-tetrazine 5d. This reaction proceeded
through the initial formation of the intermediate 40 via loss
of water, followed by intramolecular cyclization and loss of
hydrogen sulﬁde (lead acetate paper). Structure of compound
5c was supported on the basis of the elemental analysis (sulfur
free, IR, 1H NMR and mass spectral data). The IR spectrum
exhibited the absence of (C‚O) band and the presence of
NH band at 3329 cm1. 1H NMR showed signal at d
12.38 ppm for NH tetrazine ring. Mass spectrum of 5c revealed
a molecular ion peak m/z at 239 (M+, 8.03%) with a base peak
m/z at 77 (100%).
6,12-Dimethyl-4,10-diphenyl pyrimido[3,2-b]-1,2,4-5-tetra-
zino[3,2-b] pyrimidine 6 was prepared, via reﬂuxing of
Figure 4 Sample No. 3a. The inhibitory effect of compound 3a
concentration on HEPG2 cells activity.
Figure 5 Sample No. 3b. The inhibitory effect of compound 3b
concentration on HEPG2 cells activity.
Figure 6 Sample No. 4c. The inhibitory effect of compound 4c
concentration on HEPG2 cells activity.
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pound 6 was conﬁrmed by elemental analysis (sulfur free), IR
spectrum which showed the absence of (NH2) and (C‚S)
band, also, 1H NMR revealed signals at d 7.07–8.01 ppm for
aromatic protons. The mass spectrum showed a molecular
ion peak m/z at 366 (M+, 3.11%).On repeating the same reaction in xylene the mono thion
derivative 1 was obtained based on the IR data which showed
the presence of (NH2) and (C‚S) bands.
1H NMR revealed
signal at d 5.20 ppm for NH2,
13C NMR signal at values of
205 ppm for (C‚S) functionality.
In addition, phenyl acetonitrile reacted with 5-chlorosalicy-
ladehyde in ethanol piperidine (Abd El-Hamid, 1994) to give
the corresponding coumarin derivative 7. The structure of
compound 7 was established by IR, 1H NMR, and mass spec-
trometry. The interaction of compound 7 with compound 1 in
boiling ethanol afforded the corresponding N-quinolinone de-
rivative 8 (Scheme 1). Cyclization of 8 under fusion condition
with hydrazine hydrate afforded the 4,12-diphenyl-14-methyl-
pyrimido[3,2-b]-1,2,4,5-tetrazino[4,3-a] quinoline 9.
The structures of 8 and 9 were established on the basis of
their elemental analysis and spectral data. Their IR and 1H
NMR spectra proved disappearance of amino group (see ex-
perimental section) in addition to the mass spectrum of com-
pound 9 which revealed molecular ion peaks m/z at 435.5
(M+, 1.12), 437.5 (M+, 3.22) (See scheme 2).
Interaction of 1with chloroacetamide in dry DMF led to cy-
clo-condensation with elimination of HCl and H2S afforded
pyrimido[3,2-b]-1,2,4-triazin-3-one derivative 10. The IR spec-
trum showed absorption bands at 3375 cm1 and 1717 cm1
corresponding to NH and C‚O groups (Aly et al., 1995) re-
spectively, its 1H NMR spectrum showed signals at d 4.00
and 9.20 ppm assigned to (CH2CO) and (NH) groups. Both ele-
mental analysis (sulfur free) and spectral data of 10were consis-
tent with the assigned structure also, interaction of 1 with
dithiooxamide, under fusion conditions (Abd El-hamid,
1994). Structure of compound 11 was supported on the basis
of elemental analysis, IR, 1H NMR and mass spectral data.
Its IR spectrum showed absorption bands at 3383–3319 cm1
for the NH2 group. The
1H NMR showed amino protons at d
4.78 ppm, in addition to the mass spectrum which revealed a
molecular ion peak m/z at 269 (M+, 6.84%), 77 (M+, 100%).
When treating compound 1 with excess of potassium t-but-
oxide and one equivalent of p-cyano acetophenone in t-buta-
nol under reﬂux for 48 h. (Molina et al., 1985), the 1-amino
heterocycle 1 is directly converted into the corresponding 3-
(4-acetophenone)-8-methyl-6-phenyl-pyrimido[3,2-b]-1,2,4-
triazole 12 in moderate yield (50%). The reaction appears to be
quite general for aromatic nitriles; however attempts to apply
the method to aliphatic nitriles were unsuccessful. Structural
elucidation of 12 is accomplished on the basis of spectral
and elemental analysis (sulfur free) data. The 1H NMR spec-
trum showed two singlet signals at d 2.42 and 3.50 ppm as-
signed to CH3 and CH3CO protons, also, its mass spectrum
showed an intense peak at m/z= 328 (M+, 3.11%) corre-
sponding to the molecular ion. Complete information about
the 1H NMR, IR, 13 C NMR and mass spectra is presented
in the experimental section.
The synthetic approach demonstrated here was extended to
enable the synthesis of other functionally substituted pyrimi-
dine for their biological evaluation. Thus, when compound 1
was reacted with ethylamine in reﬂuxing ethanol, the 1-ami-
no-2-ethylamino-4-methyl-6-phenyl pyrimidine 13 was ob-
tained. The structure of 13 was established on the basis of
their elemental analysis and spectral data. Reﬂuxing of com-
pound 13 in acetic anhydride afforded 1-carboxyamide-2-ethy-
lamino-4-methyl-6-phenyl pyrimidine 14 (Scheme 3). Its IR
spectrum showed disappearance of NH2 and appearance of a
Figure 7 Sample No. 4d. The inhibitory effect of compound 4d
concentration on HEPG2 cells activity.
Figure 8 Sample No. 5c. The inhibitory effect of compound 5c
concentration on HEPG2 cells activity.
Figure 9 Sample No. 5d. The inhibitory effect of compound 5d
concentration on HEPG2 cells activity.
Figure 10 Sample No. 6. The inhibitory effect of compound 6
concentration on HEPG2 cells activity.
Figure 11 Sample No. 8. The inhibitory effect of compound 8
concentration on HEPG2 cells activity.
Figure 12 Sample No. 9. The inhibitory effect of compound 9
concentration on HEPG2 cells activity.
310 S.A. Al-Issanew band at 1668 cm1 for (C‚O) group. Moreover, its 1H
NMR spectrum revealed two characteristic singlet signals at
2.50 and 11.19 ppm due to methyl protons at C-4 of pyrimi-
dine moiety and NH proton, respectively. 1-(1H-pyrrol-1-yl)-
4-methyl-6-phenyl-pyrimidine-2-thione 15 was prepared, when
compound 1 was condensed with 2,5-dimethoxy tetrahydrofur-
an in glacial acetic acid. The structure of compound 15 was
conﬁrmed on the basis of elemental analysis and spectral data.The IR spectrum of 15 revealed the disappearance of the NH2
bands. Additionally, mass spectrum of 15 revealed molecular
ion peak 267 (1.02%).
Compound 1 reacted with ethyl acetoacetate to afford
ethyl-3-(4-methyl-6-phenylpyrimidine-2-thione-1-yl amino)but-
2-enoate 16. The 1H NMR of 16, oleﬁnic proton in the
side-chain resonated as a singlet at d 4.75 ppm and NH signal
was located in the region d 10.97 ppm.
Figure 13 Sample No. 10. The inhibitory effect of compound 10
concentration on HEPG2 cells activity.
Figure 15 Sample No. 12. The inhibitory effect of compound 12
concentration on HEPG2 cells activity.
Figure 16 Sample No.13. The inhibitory effect of compound 13
concentration on HEPG2 cells activity.
Figure 17 Sample No.14. The inhibitory effect of compound 14
concentration on HEPG2 cells activity.
Figure 18 Sample No.15. The inhibitory effect of compound 15
concentration on HEPG2 cells activity.
Figure 14 Sample No. 11. The inhibitory effect of compound 11
concentration on HEPG2 cells activity.
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In the present work, the synthesis of pyrimido[3,2-b]-1,2,4,5-
tetrazine 3a,b,5c,d,6,9,pyrimido[3,2-b]-1,2,4-triazine 10,11,pyri-
mido[3,2-b]-1,2,4-triazole 12 and pyrimidine derivatives
1,2a,b,4c,d,8,13,14,15,16 is reported. All spectroscopic analyses
conﬁrmed the proposed structures of these compounds. Anti-tumor activity data have shown that the synthesized com-
pounds have a signiﬁcant antitumor activity against
(HEPG2) cancer cell line.
Figure 19 Sample No. 16. The inhibitory effect of compound 16
concentration on HEPG2 cells activity.
Figure 20 Doxorubicin.
Table 1 In vitro antitumor activity of the synthesized compounds.
Comp. No Viability %
Sample concentration (lg m1)
50 25 12.5 6.2
1 22.40 67.74 86.99 9
2a 27.81 84.66 93.29 9
2b 28.72 46.99 73.91 8
3a 26.60 71.09 91.41 9
3b 19.87 69.49 84.74 9
4c 27.81 84.66 93.29 9
4d 15.83 62.88 79.62 8
5c 28.33 72.31 81.54 9
5d 26.60 71.09 91.41 9
6 45.77 71.28 86.92 9
8 28.82 77.60 91.30 9
9 31.85 76.16 89.79 9
10 26.43 73.86 87.43 9
11 33.08 74.36 83.44 9
12 38.33 79.94 87.12 9
13 26.44 79.59 97.67 10
14 21.71 62.81 72.67 8
15 24.42 66.67 85.06 9
16 24.62 76.35 87.83 9
Doxorubicinc 10.95 14.29 16.90 2
a ‘‘IC50, compound concentration required to inhibit tumor cell prolife
b Human liver cell line (HEPG2).
c Positive control.
312 S.A. Al-Issa4. Experimental
Melting points are uncorrected and were determined on a
Stuart melting point apparatus. Elemental analyses (C,H,N)
were performed on Perkin–Elmer 2400 analyzer. The IR spec-
tra (KBr) were measured on (Pye unicam SP 1000 IR spectro-
photometer). 1H NMR spectra were obtained on a Bruker
proton NMR–Avance 300 (300 MHz) using tetramethyl silane
(TMS) as internal standard. Mass spectra were run on Varian
MAT 311-A 70ev. The synthesized compounds were screened
in vitro antitumor activity at the regional center for mycology
and biotechnology, Al-AZHAR UNIVERSITY.
4.1. 1-Amino-4-methyl-6-phenyl pyrimidin-2-thione 1
A mixture of benzoyl acetone (0.01 mol) and thiosemicarba-
zide (0.01 mol) in ethanol (50 ml) containing 3 drops of piper-
idine was reﬂuxed for 5 h. The reaction mixture was
concentrated and allowed to cool and the solid obtained was
recrystallized from ethanol. Yield 79%; m.p. 160–162 C; IR
(KBr, cm1) 3361, 3308 (NH2), 3050 (CH arom.), 2922 (CH
aliph.), 1644 (C‚N), 1216 (C‚S). 1H NMR (DMSO-d6) d
2.35 (s, 3H, CH3), 5.70 (s, 2H, NH2), 7.30–8.20 (m, 5H, Ar-
H), 8.65 (s, 1H, (H-5) pyrimidine); 13C NMR: d 16.10 (CH3),
111.18–145.10 (Caromatic), 205.00 (C‚S); MS, m/z (%): 217
[M+, 3.37], 77 [100]. Anal. Calcd. For: C11H11N3S: C, 60.82;
H, 5.06; N, 19.35; S, 14.74. Found: C, 60.55; H, 5.00; N,
19.50; S, 14.80.IC50(lg/ml)
a HEPG2b
5 3.12 1.56
7.83 100.0 100.0 34.8
9.12 100.0 100.0 17.4
9.63 98.12 100.0 23.6
8.18 100.0 100.0 36.5
1.09 98.46 100.0 34.8
9.12 100.0 100.0 40.2
7.44 96.92 100.0 31.8
5.86 100.0 100.0 37.7
8.18 100.0 100.0 36.9
7.24 100.0 100.0 45.9
8.11 100.0 100.0 38.30
6.84 100.0 100.0 39.8
6.07 100.0 100.0 37.6
6.18 100.0 100.0 39.8
6.86 100.0 100.0 43.0
0.0 100.0 100.0 38.9
5.44 96.39 100.0 32.8
7.48 100.0 100.0 34.9
6.14 100.0 100.0 37.7
1.03 30.32 100.0 1.2
ration by 50%’’.
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thioxo)pyrimidinyl]thiourea 2a, N-phenyl-N
0-1-[(4-methyl-6-
phenyl-2-thioxo)pyrimidinyl]thiourea 2b
Thenoyl isothiocyanate or phenyl isothiocyanate (0.005 mol)
was added to a solution of compound 1 (0.005 mol) in 20 ml
of acetonitrile. The resulting solution was stirred and heated
under reﬂux for 18 h. (A solid formed during the course of
the reaction). The reaction mixture was cooled and the solid
was removed by ﬁltration, dried and recrystallized from etha-
nol to give, 2a; yield 64%; m.p. 190–192 C; IR (KBr, cm1):
3242, 3135 (2NH), 3020 (CH arom.), 2974 (CH aliph.) 1660
(C‚O), 1238 (C‚S); 1H NMR (DMSO-d6) d 2.50(s,
3H,CH3), 10.00 (br. s, 1H, NH), 12.79 (br. s, 1H, NH),
8.08–7.27 (m, 9H, Ar-H; pyrimidine H-5); Anal. Calcd. For
C17H14ON4S3: C, 52.84; H, 3.62; N, 14.50; S, 24.87; Found:
C, 52.55, H, 3.33; N, 14.80; S, 25.00.
2b, yield, 60%; m.p. 220–222 C; IR(KBr, cm1): 3280,
3200 (2NH), 3100 (CH arom.), 2920 (CH aliph), 1220
(C‚S); 1H NMR (DMSO-d6) d 10.11 (br. s,2H, 2NH); 7.78–
7.50 (m, 11H, Ar-H, pyrimidin H-5); Anal. Calcd. For
C18H16N4S2: C, 61.36; H, 4.54; N, 15.90; S, 18.18. Found: C,
61.30; H, 4.50; N, 16.00 S, 18.50.
4.3. 9-Methyl-7-phenyl-4-(2-thenoyl amino) (3H)
pyrimido[3,2-b]-1,2,4,5-tetrazine 3a, 9-methyl-7-phenyl-4-
phenylamino (3H) pyrimido[3,2-b]-1,2,4,5-tetrazine 3b
A mixture of compound 2a or b (0.01 mol) and hydrazine hy-
drate (0.01 mol) was fused on an oil bath at 165 C for 4 h.,
the solid obtained was recrystallized from ethanol, 3a; yield
55%; m.p. 140–142 C; IR (KBr, cm1):3463(OH), 3305,
3259 (2NH), 3020 (CH arom.), 2888 (CH aliph.), 1665
(C‚O), 1640 (C‚N); 1H NMR (DMSO-d6) d: 2.50 (s, 3H,
CH3), 7.33–8.08 (m, 8H, Ar-H), CH-pyrimidine), 9.85 (s, 1H,
NH), 12.79 (s, 1H, NH); 13C NMR (DMSO-d6) d 20.28
(CH3), 111.00–150.03 (Caromatic), 180.22 (C‚O); Ms, m/z
(%): 350 [M+] (2.72), 77 (100), Anal. Calcd. For C17H14ON6S:
C, 58.28; H, 4.00; N, 24.00; S, 9.14; Found: C, 58.50; H, 4.11;
N, 24.28, S, 9.50.
3b, yield 50%; m.p. 170–172 C; IR (KBr, cm1): 3336, 3266
(2NH), 3050 (CH arom.), 2992 (CH aliph.), 1618 (C‚N); 1H
NMR (DMSO-d6) d: 2.38 (s, 3H, CH3), 7.18–7.90 (m, 10H, Ar-
H), 8.05 (s, 1H, CH-pyrimidine), 11.18 (s, 1H, NH), 13.90 (s,
1H, NH); MS, m/z (%): 316 (1.11), 77 (100); Anal. Calcd.
For C18H16N6: C, 68.35; H, 5.06, N, 26.58; Found: C, 68.30;
H, 5.00, N, 26.60.
4.4. 1-Carboxamide-4-methyl-6-phenyl-pyrimidine-2-thione 4c;
1-(2-thenoyl amino)-4-methyl-6-phenyl-pyrimidine-2-thione 4d
A solution of 1 (0.01 mol) in acetyl chloride or thenoyl chloride
(10 ml) was reﬂuxed for 4 h. Decomposition over ice-cold
water gave a solid that recrystallized from ethanol 4c: yield,
55%; m.p. 260–262 C; IR (KBr, cm1) 3320 (OH), 3190
(NH), 3005 (CH arom), 2999 (CH aliph.), 1695 (C‚O), 1644
(C‚N), 1228 (C‚S); 1H NMR (DMSO-d6) d 2.28 (s, 3H,
CH3), 3.80 (s, 3H, CH3), 7.13–8.80 (m, 6H, Ar-H), 9.98,10.76 (2s, 1H, HNC‚O and N‚C–OH), 11.33 (s, 1H,
HNCOCH3); Anal. Calcd. For: C13H13ON3S: C, 60.23; H,
5.01; N, 16.21; S, 12.35. Found: C, 60.30; H, 5.00, N, 16.28;
S, 12.30.
4d, yield, 62%; m.p. 295–297 C; IR (KBr, cm1): 3320
(OH), 3190 (NH) 3100 (CH arom.), 2980 (CH aliph.), 1690
(C‚O), 1644 (C‚N), 1220 (C‚S) 1H NMR (DMSO-d6) d
2.32 (s, 3H, CH3); 7.33–7.44 (m 9H, Ar-H); 9.81, 9.13 (2s,
1H, HNC‚O and N‚C–OH), 10.68 (s, 1H, HNCOR); Anal.
Calcd. For: C16H13ON3S2: C, 58.71; H, 3.97; N, 12.84; S,
19.57. Found: C, 58.70; H, 4.00; N, 12.80, 5, 19.62.
4.5. 4,9-Dimethyl-7-phenyl (3H) pyrimido[3,2-b]-1,2,4,5-
tetrazine 5c and 9-methyl-7-phenyl-4-(2-thienyl) (3H)
pyrimido[3,2-b]-1,2,4,5-tetrazine 5d
A mixture of compound 4c or d (0.01 mol) and hydrazine hy-
drate (0.01 mol) was fused in an oil bath at 180 C for 4 h.
The solid obtained was recrystallized from ethanol;
5c yield 50%; m.p. 140–142 C; IR (KBr, cm1) 3329 (NH),
3095 (CH arom.), 2980–2888 (CH aliph.), 1640 (C‚N), 1H
NMR (DMSO-d6) d 2.30 (s, 3H, CH3), 2.50 (s, 3H, CH3),
7.85–8.11 (m, 6H, Ar-H), 12.38 (s, 1H, NH); MS, m/z (%):
239 [M+] (8.03), 77 [100]. Anal. Calcd. for: C13H13N: C,
66.27; H, 5.43; N, 29.28. Found: C, 66.20; H, 5.50; N, 29.80.
5d yield 57%; m.p. 240–242 C; IR (KBr, cm1): 3300
(NH), 3055 (CH arom.), 2988 (CH aliph.), 1648 (C‚N), 1H
NMR (DMSO-d6) d 2.33 (s, 3H, CH3), 7.32–8.11 (m, 8H,
Ar-H), 9.52 (s, 1H, C–H pyrimidine), 12.99 (s, 1H, NH);
MS, m/z (%): 307 [M+] (3.11), 77 [100]. Anal. Calcd. For:
C16H13N5S: C, 62.54; H, 4.23; N, 22.80, S, 10.42. Found: C,
62.54; H, 4.23; N, 22.80; S, 10.42.
4.6. 6,12-Dimethyl-4,10-diphenyl pyrimido[3,2-b]-1,2,4,5-
tetrazino[3,2-b] pyrimidin 6
A solution of 1 (0.01 mol) in pyridine (20 ml) was reﬂuxed for
48 h. The reaction mixture was poured into ice cold water and
the obtained solid was recrystallized from dioxan; yield 62%,
m.p. >360 C; IR (KBr, cm1) 3055 (CH arom.), 2995–2870
(CH aliph.); 1H NMR (DMSO-d6) d 2.42 (s, 6H, 2CH3),
7.07–8.01 (m, 12H, Ar-H); MS, m/z (%): 366 [M+] (3.11), 77
[100] Anal. Calcd. For: C22H18N6: C, 72.13; H, 4.91; N,
22.95. Found: C, 72.00; H, 5.00, N, 22.80.
4.7. 6-Chloro-3-phenyl coumarine 7
A mixture of the appropriate phenylacetonitrile (0.005 mol)
and 5-chloro-salicyladehyde (0.005 mol) in ethanol (35 ml)
containing piperidine (5 drops) was reﬂuxed for 4 h. The reac-
tion mixture was cooled and then acidiﬁed with dilute hydro-
chloric acid. The solid so formed was collected and
recrystallized from ethanol, yield 80%; m.p. 200–202 C; IR
(KBr, cm1) 3050 (CH arom.), 1680 (C‚O), 1600 (C‚C);
1H NMR (DMSO-d6) d 7.00–8.22 (m, 9H, Ar-H); MS, m/z
(%): 256.5 [M+] (3.11), 258.5 [M+] (11.22), 77 (100). Anal.
Calcd. For: C15H9O2Cl: C, 70.17; H, 3.50; Cl, 13.84. Found:
C, 70.30; H, 3.33; Cl, 14.00.
314 S.A. Al-Issa4.8. 6-Methy-4-phenyl-3[3-phenylquinoline-2-one] pyrimidin-2-
thione 8
A mixture of 1 (0.01 mol) and 3-phenyl-6-chloro coumarin 7
(0.012 mol) was reﬂuxed in ethanol (50 ml) for 12 h. the solid
product was recrystallized from dioxane; yield 65%; m.p.
120–122 C; IR (KBr, cm1) 3055 (CH arom.), 2900–2880
(CH aliph.), 1680 (C‚O), 1222 (C‚S), 1648 (C‚N), 1600
(C‚C). 1H NMR (DMSO-d6) d 2.33 (s, 3H, CH3), 7.29–8.41
(m, 15H, Ar-H). Anal. Calcd. For: C26H18ClON3S: C, 68.49;
H, 3.95; N, 9.22; Cl, 7.79; S, 7.02 Found: C, 68.50, H, 3.70,
N, 9.50, Cl, 7.80, S, 7.12.4.9. 4,12-Diphenyl-14-methyl pyrimido[3,2-b]-1,2,4,5-
tetrazino[4,3-a] quinoline 9
A mixture of compound 8 (0.01 mol) and hydrazine hydrate
(0.01 mol) was reﬂuxed for 4 h. The reaction mixture was
cooled and the solid obtained was recrystallized from dioxane,
yield 79%; m.p. >360 C, IR (KBr, cm1) 3105 (CH arom.),
2989 (CH aliph.); 1H NMR (DMSO-d6) d 2.33 (s, 3H, CH3),
7.29–8.38 (m, 16H, Ar-H); M, m/z (%): 435.5 [M+] (1.12),
437.5 [M+] (3.22), 77 (100). Anal. Calcd. For: C26H18N5Cl:
C, 71.64; H, 4.13; N, 16.07, Cl, 8.15. Found: C, 71.80; H,
4.00; N, 16.00; Cl, 8.30.4.10. 9-Methyl-7-pheny-(5H) pyrimido[3,2-b]-1,2,4-triazin-3-
one 10
A mixture of compound 1 (0.005 mol) and chloroacetamide
(0.005 mol) in dry DMF (30 ml) was reﬂuxed for 48 h. The re-
action mixture was cooled, the solid was ﬁltered off and recrys-
tallized from DMF. Yield 53%; m.p. 320–322 C. IR (KBr
cm1) 3375 (NH), 3055 (CH arom.), 2988 (CH aliph.), 1717
(C‚O), 1640 (C‚N) 1H NMR (DMSO-d6) d 2.49 (s, 3H,
CH3) 4.00 (s, 2H, CH2CO), 7.49–7.99 (m, 5H, Ar-H), 8.00
(s, 1H, CH-pyrimidine), 9.20 (s, 1H, NH); 13C NMR: d 11.4
(CH3), 61.30 (CH2), 101.00, 110.00, 118.20, 119.80, 142.70,
148.20, 149.20, 150.11, 153.40, 155.50, (Caromatic), 180.60
(C‚O). MS (m/z) (%): 240 (M+), 6.09), 77 (100).
Anal. Calcd. For: C13H12N4O: C, 65.00. H, 5.00; N, 23.33.
Found: C, 65.11; H, 5.28; N, 23.50.4.11. 4-Amino-9-methyl-7-phenyl pyrimido[3,2-b]-1,2,4-triazin-
3-thione 11
A mixture of compound 1 (0.01 mol) and dithiooxamide
(0.01 mol) was fused on an oil bath at 175 C for 4 h., the solid
product was recrystallized from ethanol; yield, 70%; m.p.
>360; IR (KBr, cm1) 3383–3319 (NH2), 3005 (CH arom.),
2900 (CH aliph), 1644 (C‚N), 1222 (C‚S). 1H NMR
(DMSO-d6) d 2.33 (s, 3H, CH3), 4.78 (s, 2H, NH2), 7.11–
7.71 (m, 6H, Ar-H), 13C NMR: d 11.40 (CH3), 112.20–
142.11, Caromatic; 200.00 (C‚S); MS, m/z (%): 269 [M
+]
(6.84), 77 [100]. Anal. Calcd. For: C13H11N5S: C, 57.99; H,
4.08; N, 26.02; S, 11.89; Found: C, 57.30; H, 4.00; N, 26.38.4.12. 3-(4-Acetophenone)-8-methyl-6-phenyl pyrimido[3,2-
b]1,2,4-triazole 12
A mixture of compound 1 (10 mmol), p-cyanoacetophenone
(10 mmol), and Potassium t-butoxide (20 mmol) in t-butanol
(50 ml) was reﬂuxed for 48 h. After cooling, the solvent was
evaporated under reduced pressure, the crude product was
washed with cold water (50 ml), separated by ﬁltrations and re-
crystallized from ethanol to give 12, yield 50%; m.p. 260–
262 C. IR (KBr cm1) 3055 (CH arom), 2999–3880 (CH
aliph), 1648 (C‚N); 1H NMR (DMSO-d6) d 2.42, 3.50 (2s,
6H, (CH3) and (CH3CO) 7.52–8.80 (m, 10H, Ar–H),
13C
NMR: d 10.13 (CH3), 30.13 (CH3CO), 114.11–139.01
Caromatic.; MS (m/z): 328 [M
+] (3.11), 76 (100). Anal. Calcd.
For: C20H16N4O: C, 73.17; H, 4.87; N, 17.07 Found: C,
73.00; H, 4.80; N, 17.31.
4.13. 1-Amino-2-ethylamino-4-methyl-6-phenyl-pyrimidine 13
A mixture of compound 1 (0.01 mol) and ethyl amine
(0.01 mol) in ethanol (30 ml) was heated under reﬂux for 2 h.
After cooling, the solid formed was collected and recrystallized
from ethanol yield 72%m.p. 190–192 C; IR (KBr cm1) 3400,
3300 (NH2), 3050 (CH arom.), 2900–2880 (CH aliph.) 1640
(C‚N); 1H NMR (DMSO-d6) d 2.33 (s, 3H, CH3) 1.33
(t, 3H, CH2CH3, J= 9.22 Hz), 4.23 (q, 2H, CH2CH3,
J= 11.82 Hz), 7.22–7.82 (m, 5H, Ar-H), 8.81 (s, 1H, CH-pyr-
imidine); Anal. Calcd. For C13H16N4: C, 68.42; H, 7.01; N,
24.56; Found: C, 68.60, H, 7.18; N, 24.60.
4.14. 1-Carboxyamid-2-ethylamino-4-methyl-6-phenyl-
pyrimidine 14
A solution of compound 13 (0.005 mol) in acetic anhydride
(20 ml) was heated for 10 min. The solvent was evaporated un-
der reduced pressure, then the reaction mixture was poured
into ice-water (40 ml) to give a solid precipitate which was ﬁl-
tered off and recrystallized from petroleum ether 60/80 to give
14.; yield 65%; m.p. 300–302 C. IR (KBr cm1) 3183 (NH),
3057 (CH arom.), 2900–2882 (CH aliph.), 1637 (C‚N), 1668
(C‚O). 1H NMR (DMSO-d6) 2.50 (s, 3H, CH3), 2.64 (s,
3H, CH3CO), 1.14 (t, 3H, CH2CH3, J= 8.22 Hz), 4.25 (q,
2H, CH2CH3), J= 11.30 Hz), 7.06–7.95 (m, 5H, Ar-H),8.32
(s, 1H, CH-pyrimidine), 11.19 (s, 1H, NH). Anal. Calcd. For
C15H18N4O: C, 66.66, H, 6.66, N,20.74. Found: C, 66.50; H,
6.51; N, 20.70.4.15. 1-(1H-Pyrrol-1-yl)-4-methyl-6-phenyl-pyrimidin-2-thione
15
A solution of compound 1 (0.09 mol), and 2,5-dimethoxytetra-
hydrofuran (0.13 mol) in glacial acetic acid (25 ml) was re-
ﬂuxed for 6 h. The reaction mixture was concentrated and
the obtained solid was recrystallized from (ethanol-dioxane;
1:1); yield 72%; m.p. >360 C; IR (KBr cm1) 3090 (CH
arom.), 2990 (CH aliph.) 1646 (C‚N), 1222 (C‚S); 1H
NMR (DMSO-d6) d 2.50 (s, 3H, CH3), 7.19–7.95 (m, 9H,
Synthesis and anticancer activity of some fused pyrimidines and related heterocycles 315Ar-H and CH-pyrrol) 8.32 (s, 1H, CH-pyrimidine); MS: m/z
(%): 267 [M+] (1.02), 77 (100). Anal. Calcd. For:
C15H13N3S: C, 67.41; H, 4.86; N, 15.73; S, 11.98. Found: C,
67.50; H, 4.90; N, 16.00; S, 11.90.
4.16. Ethyl-3-(4-methyl-6-phenyl-pyrimidine-2-thione-1-yl-
amino) but-2-enoate 16
A mixture of 1(5.62 mmol) and (8 ml) of ethylacetoacetate was
heated for 8 h. Excess ethylacetoacetate was distilled off under
reduced pressure and the, residue was puriﬁed by recrystalliza-
tion from ethanol; yield 50%; m.p. >360 C; IR (KBr cm1):
3220 (NH), 3070 (CH arom.), 2900–2780 (CH aliph.), 1710
(C‚O), 1220 (C‚S), 1H NMR (DMSO-d6) d 1.19 (t, 3H,
OCH2CH3, J= 8.11 Hz) 2.50 (s, 3H, CH3), 2.73 (s, 3H,
CH3), 4.35 (q, 2H, OCH2, J= 11.15 Hz), 4.75 (s, 1H, CH),
7.22–7.78 (m, 5H, Ar-H), 8.32 (s, 1H, CH-pyrimidine); 10.97
(s, 1H, NH). Anal. Calcd. For: C17H19N3O2S: C, 62.00; H,
5.77; N, 12.76; S, 9.72. Found: C, 62.18; H, 5.50; N, 12.70;
S, 10.00.
5. Biological testing
5.1. Materials
Doxorubicin, the reference drug used in this study, is one of
the most effective antitumor agents.
HEPG2 cells (human cell line of a well differentiated hepa-
tocellular carcinoma isolated from a liver biopsy of male Cau-
casian aged 15 years) were obtained from the American type
culture collection (ATCC). All other chemicals were obtained
from sigma chemical company (st. Louis, Mo., USA).
5.2. Evaluation of celllular cytotoxicity
The cytotoxic activity of the target compounds against
HEPG2 cells was determined using cytotoxicity assay. In brief,
the cells were seeded in a 96-well plate at a cell concentration
of 1 · 104 cell per well in 100 ll of growth medium and fresh
medium containing different concentrations of the test sample
was added after 24 h of seeding. Serial twofold dilution of the
tested chemical compound was added to conﬂuent cell mono-
layers dispensed into 96-well, ﬂat-bottomed microtiter plates
(Falcon, NJ, USA) using a multichannel pipette. The microti-
ter plates were incubated at 37 C in a humidiﬁed incubator
with 5% CO2 for a period of 48 h. Three wells were used for
each concentration of the test sample. Control cells were incu-
bated without test sample and with or without DMSO. The
low percentage of DMSO present in the wells (maximal
0.1%) was found not to affect the experiment. After incuba-
tion of the cells for 24 h at 37 C, various concentrations of
sample (50, 25, 12.5, 6.25, 3.125 & 1.56 lg) were added, and
the incubation was continued for 48 h and viable cell yield
was determined by a colorimetric method. In brief, after the
end of the incubation period, media were aspirated and the
crystal violet solution (1%) was added to each well for at least
30 min. The stain was removed and the plates were rinsed
using tap water until all excess stain was removed. Glacial
acetic acid (30%) was then added to all wells and mixed thor-
oughly, and then the absorbances of the plates were measuredafter gently shaking on microplate reader, using a test wave-
length of 490 nm. All results were corrected for background
absorbance detected in wells without added stain. Treated
samples were compared with the cell control in the absence
of the tested compounds. All experiments were carried out in
triplicate. The cell cytotoxic effect of each tested compound
was calculated (Mosmann, 1983; Vijayan et al., 2004) (Figs.
1–20).5.3. Evaluation of cytotoxicity activity against the human liver
cancer (HEPG2) cell line
The antitumor activities of compounds were assessed against
HEPG2 cancer cell line in comparison to the traditional antic-
ancer drug (Doxorubicin) on the basis of monitoring the inhi-
bition of the growth of human cancer cells, a series of
synthesized compounds possessing a broader spectrum of anti-
tumor activity. Ninety tested compounds (1; 2a,b; 3a,b; 4c,d; 5c,d;
6;8;9;10;11;12;13;14;15 and 16) were subjected to a screening
system for investigation of their antitumor potency against li-
ver (HEPG2) cell line. The antitumor activity results indicated
that most of the compounds showed inhibition activity against
the tested cell line but varying intensity extents in comparison
to the known anticancer drug (Doxorubicin) (See Table 1).
Compounds 2a,b showed signiﬁcant in vitro antitumor ac-
tivity (IC50, 17.4 lg/ml, 23.6 lg/ml) and possess thiouredo
moiety which is known to have antitumor activity (Abou El
Ella et al., 2008; Agrawal et al., 2002). Also, fusion of pyrimi-
do[3,2-b]-1,2,4,5-tetrazine in tri(or) tetracyclic structure
namely pyrimido tetrazinopyrimidine (6) (IC50, 45.9 lg/ml)
or pyrimidotetrazino quinoline (9) (IC50, 39.8 lg/ml) enhances
the antitumor activity.References
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